Clinical data | |
---|---|
Trade names | Megace, others |
Other names | MGA; BDH-1298; NSC-71423; SC-10363; 17α-Acetoxy-6-dehydro-6-methylprogesterone; 17α-Acetoxy-6-methylpregna-4,6-diene-3,20-dione |
License data | |
Routes of administration | By mouth |
Drug class | Progestogen; Progestin; Progestogen ester; Antigonadotropin; Steroidal antiandrogen |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 100%[2] |
Protein binding | 82% to albumin,[3] no affinity for SHBG or CBG[2][4] |
Metabolism | Liver (hydroxylation, reduction, conjugation)[6] |
Elimination half-life | Mean: 34 hours[5] Range: 13–105 hours[5] |
Excretion | Urine: 57–78%[6] Feces: 8–30%[6] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.008.969 |
Chemical and physical data | |
Formula | C24H32O4 |
Molar mass | 384.516 g·mol−1 |
3D model (JSmol) | |
| |
|
Megestrol acetate (MGA), sold under the brand name Megace among others, is a progestin medication which is used mainly as an appetite stimulant to treat wasting syndromes such as cachexia.[2][5][7][1] It is also used to treat breast cancer and endometrial cancer, and has been used in birth control.[5][7][8][9] Megestrol acetate is generally formulated alone, although it has been combined with estrogens in birth control formulations.[10] It is usually taken by mouth.[2]
Side effects of megestrol acetate include increased appetite, weight gain, vaginal bleeding, nausea, edema, low sex hormone levels, sexual dysfunction, osteoporosis, cardiovascular complications, glucocorticoid effects, and others.[7] Megestrol acetate is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.[2] It has weak partial androgenic activity, weak glucocorticoid activity, and no other important hormonal activity.[2] Due to its progestogenic activity, megestrol acetate has antigonadotropic effects.[7] The mechanism of action of the appetite stimulant effects of megestrol acetate is unknown.[11][12][13]
Megestrol acetate was discovered in 1959 and was introduced for medical use, specifically in birth control pills, in 1963.[8][9][14] It may be considered a "first-generation" progestin.[15] The medication was withdrawn in some countries in 1970 due to concerns about mammary toxicity observed in dogs, but this turned out not to apply to humans.[16][17][18][19][20] Megestrol acetate was approved for the treatment of endometrial cancer in 1971 and wasting syndromes in 1993.[7][21] It is marketed widely throughout the world.[22][23] It is available as a generic medication.[24]
ChuLi1986b
was invoked but never defined (see the help page).Marks2010
was invoked but never defined (see the help page).pmid13934321
was invoked but never defined (see the help page).MortonHall1999
was invoked but never defined (see the help page).BergerShuster2006
was invoked but never defined (see the help page).Jörres2010
was invoked but never defined (see the help page).Ettinger2008
was invoked but never defined (see the help page).Springer2012
was invoked but never defined (see the help page).UnitedNations1983
was invoked but never defined (see the help page).pmid4126857
was invoked but never defined (see the help page).FDAConsumer1976
was invoked but never defined (see the help page).Welfare1976
was invoked but never defined (see the help page).RunnebaumRabe2012b
was invoked but never defined (see the help page).EiblEdderkaoui2015
was invoked but never defined (see the help page).IndexNominum2000
was invoked but never defined (see the help page).Drugs.com
was invoked but never defined (see the help page).